DFDA

Autologous Stem Cell Transplant (ASCT)

Treatment for Burkitt Lymphoma

Typical Dosage: High-dose conditioning chemotherapy followed by stem cell reinfusion

Effectiveness
50%
Safety Score
25%
Clinical Trials
5
Participants
2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
High-dose conditioning chemotherapy followed by stem cell reinfusion
Time to Effect
Weeks to months for engraftment and recovery
Treatment Duration
3-4 weeks inpatient for transplant, months for recovery
Evidence Quality
MODERATE
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$75,000
Monitoring:$200,000
Side Effect Mgmt:$125,000
Total Annual:$400,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$100,000/QALY
QALYs Gained
4
Outcome-Based Costs
Cost per Remission
$1,000,000
Autologous Stem Cell Transplant (ASCT) Outcomes

for Burkitt Lymphoma

Efficacy Outcomes
Overall Effectiveness
+50%
Remission Rate
+40%
Common Side Effects
Profound Myelosuppression
+95%
Severe Febrile Neutropenia/Infection
+80%
Severe Mucositis/Stomatitis
+85%
Nausea/Vomiting
+90%
Fatigue
+90%
Organ Toxicity (Renal, Hepatic, Pulmonary)
+30%
Secondary Malignancies (long term)
+7%

Sources:

researchgate.net
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
4 completed trials for Autologous Stem Cell Transplant (ASCT) in Burkitt Lymphoma

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00536601COMPLETEDNA
View Study
174 participants
INTERVENTIONAL
Buffalo, United States
Started: Jun 29, 2006

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00073918COMPLETEDPHASE2
View Study
111 participants
INTERVENTIONAL
Seattle, United States
Started: Feb 1, 1999

Radiation Therapy in Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation

NCT00031668COMPLETEDNA
View Study
6 participants
INTERVENTIONAL
Calgary, Canada +8 more
Started: Jan 31, 2001

Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma

NCT01516593COMPLETEDPHASE2
View Study
19 participants
INTERVENTIONAL
Aviano (PN), Italy +7 more
Started: Nov 1, 2011